- 2015
- Press releases - 07.01.2015
Huntington’s disease: therapeutic potential of triheptanoin confirmed
A team of researchers from Inserm led by Fanny Mochel and located at the Brain and Spinal Cord Institute (Inserm/CNRS/UPMC/AP-HP) has just demonstrated the therapeutic potential of triheptanoin in ten patients with Huntington’s disease.
- News in brief - 07.01.2015
Resident and recruited macrophages orchestrate the liver’s defense against infection
Macrophages are key cells of the innate immune system. By capturing and ingesting microbes in a process known as phagocytosis, they play an important role in defending host tissues against infection. There are two types of macrophage: tissue-resident macrophages, and bone marrow monocytes that circulate in the bloodstream and are recruited in tissues during infection […]
- 2014
- Press releases - 19.12.2014
Gastroenteritis for holiday season
In metropolitan France last week, the incidence rate for cases of acute diarrhoea seen in general practice was estimated at 253 cases per 100,000 inhabitants, i.e. 160,000 new cases, higher than the previous week, and just below the epidemic threshold (269 cases per 100,000 inhabitants).
- Press releases - 19.12.2014
Blood group O associated with a lower risk of developing type 2 diabetes
Is there a relationship between blood group and the risk of developing type 2 diabetes? This is the question studied by Guy Fagherazzi and his collaborators from Joint Research Unit 1018, “Centre for Research in Epidemiology and Population Health” (Inserm/University Paris-Sud) at Gustave Roussy Institute.
- What's on? - 19.12.2014
Gastroenteritis for holiday season
In metropolitan France last week, the incidence rate for cases of acute diarrhoea seen in general practice was estimated at 253 cases per 100,000 inhabitants, i.e. 160,000 new cases, higher than the previous week, and just below the epidemic threshold (269 cases per 100,000 inhabitants). At regional level, the highest rates of incidence were found […]
- Press releases - 17.12.2014
A mechanism for eliminating proteins accidentally localised to the cell nucleus
An international collaboration coordinated by the German Cancer Research Center (DKFZ) (University of Heidelberg), including French researchers from the Institute of Genetics and Development of Rennes (IGDR) (CNRS/University of Rennes 1) under the leadership of Gwenaël Rabut, Inserm Researcher, and teams from Sweden and Canada, has just demonstrated a new molecular mechanism that may allow cells to destroy proteins accidentally localised to the nucleus.
- Press releases - 15.12.2014
Valérie Mazeau-Woynar appointed Director of the Department of Partnerships and External Relations (DPRE) at Inserm
Valérie Mazeau-Woynar succeeds Claire Giry at the head of Inserm’s Department of Partnerships and External Relations (DPRE). In this role, she will contribute to the implementation of Inserm’s institutional partnerships at regional, national, European and international level, at the behest of Directorate General, and in coordination with the Thematic Institutes.
- Press releases - 12.12.2014
Improved understanding of the diabetic process via the Rfx6 gene
For the first time, the team led by Gérard Gradwohl, an Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology, Illkirch (IGBMC/Inserm-CNRS-University of Strasbourg), has shown that the Rfx6 gene is essential for the functioning of the cells that produce insulin, the pancreatic beta cells.
- Press releases - 08.12.2014
Ebola Virus: Detailed notice for the clinical trial being launched in Guinea
The pilot clinical trial conducted by Inserm is aimed at testing the efficacy of favipiravir in reducing mortality in individuals infected by Ebola virus in Guinea.
- What's on? - 08.12.2014
Ebola Virus: Detailed notice for the clinical trial being launched in Guinea
In Guinea, the epidemic caused by Ebola infection is still in the active phase nearly one year after it began. It is essential that measures for surveillance, control and management be accompanied by study of innovative therapies in order to reduce mortality. Potentially useful drugs include favipiravir (T-705), an antiviral drug already tested against influenza […]